Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Safety and compatibility of smart device heart rhythm monitoring in patients with cardiovascular implantable electronic devices
Abudan, Anas, Isath, Ameesh , Ryan, J. , Henrich, Mark, Dugan, Jennifer , Ladewig, Dorothy J., Friedman, Paul A. , Abudan, Anas A , Ryan, James D , Henrich, Mark J, Dugan, Jennifer L, Dillon, John J, Friedman, Paul A , Attia, Zachi I. , Dillon, John

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 13, 2019 | Volume: 30 | Issue: 9 | Pages: 1602-1609

10.1111/jce.14024 | PMID 31190453 Get It

AbstractIntroductionEmerging medical technology has allowed for monitoring of heart rhythm abnormalities using smartphone compatible devices. The safety and utility of such devices have not been established in patients with cardiac implantable electronic devices (CIEDs). We sought to assess the safety and compatibility of the Food and Drug Administration‐approved AliveCor Kardia device in patients with CIEDs.Methods and ResultsWe prospectively recruited patients with CIED for a Kardia recording during their routine device interrogation. A recording was obtained in paced and nonpaced states. Adverse clinical events were noted at the time of recording. Electrograms (EGMs) from the cardiac device were obtained at the time of recording to assess for any electromagnetic interference (EMI) introduced by Kardia. Recordings were analyzed for quality and given a score of 3 (interpretable rhythm, no noise), 2 (interpretable rhythm, significant noise) or 1 (uninterpretable). A total of 251 patients were recruited (59% with a pacemaker and 41% with ICD). There were no adverse clinical events noted at the time of recording and no changes to CIED settings. Review of all EGMs revealed no EMI introduced by Kardia. Recordings were correctly interpreted in 90% of paced recordings (183 had a score of 3, 43 of 2, and 25 of 1) and 94.7% of nonpaced recordings (147 of 3, 15 of 2, and 9 of 1).ConclusionThe AliveCor Kardia device has an excellent safety profile when used in conjunction with most CIEDs. The quality of recordings was preserved in this population. The device, therefore, can be considered for heart rhythm monitoring in patients with CIEDs.
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP
Nowakowski, Grzegorz S. , Macon, Rita E., King, Rebecca L. , Wagner‐Johnston, Nina, Wade, James L. , Nagargoje, Gauri G., Reynolds, Christopher M. , Cohen, Jonathon B. , Amengual, Jennifer E. , Richards, Kristy L. , Little, Richard F. , Leonard, John P. , Friedberg, Jonathan W. , Kostakoglu, Lale , Kahl, Bradley, Hong, Fangxin , Scott, David W. , Habermann, Thomas M. , Casulo, Carla , Khan, Niloufer , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 37-38

10.1002/hon.6_2629 Get It

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)
Topp, Max S. , Arnason, Jon , Brown, Jennifer R. , Allan, John N. , Ansell, Stephen M. , Duell, Johannes , Rosenwald, Andreas , Charnas, Robert L., Ambati, Srikanth, Adriaens, Lieve, Ufkin, Melanie, Li, J. , Gasparini, Peter, Janković, Vladimir , Fiaschi, Nathalie , Zhang, W., Hamon, Sara , Yancopoulos, George D., Lowy, Israel , Sternberg, David , Advani, Ranjana H. , O’Brien, Susan , Chavez, Julio C , Zhu, Min , Thurston, Gavin , Murphy, Andrew James , Bannerji, Rajat

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 90-92

10.1002/hon.58_2629 Get It

ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY
Witzig, T.E. , Maddocks, Kami J. , Vos, Sven de , Lyons, Roger M. , Edenfield, WJ, Sharman, Jeff P. , Yimer, Habte, Chan, Emily , Patel, Pankaj , Simone, Christopher Di, Gandhi, M., Vaughn, Jennifer E. , Cheson, Bruce D. , Samaniego, Felipe , Vose, Julie M. , Wei, Helen , Patel, P., Vaughn, J., Kolibaba, Kathryn S.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 327-328

10.1002/hon.139_2630 Get It

Immune Reconstitution Inflammatory Syndrome as a Posttransplantation Complication in Primary Immunodeficiency With Disseminated Mycobacterium avium
Manion, Maura , Dimitrova, Dimana , Pei, Luxin , Gea‐Banacloche, Juan , Lisco, Andrea , Zerbe, Christa S. , Freeman, Alexandra F. , Holland, Steven M. , Kanakry, Christopher G. , Kanakry, Jennifer A. , Zelazny, Adrian M. , Sereti, Irini

Mayo Clinic

Clinical Infectious Diseases | June 11, 2019 | Volume: 70 | Issue: 4 | Pages: 676-679

10.1093/cid/ciz507 | PMID 31190050 Get It

Abstract Patients with primary immunodeficiencies undergoing allogeneic hematopoietic cell transplantation (HCT) for difficult-to-control infections can experience immune reconstitution inflammatory syndrome (IRIS) following engraftment. In 3 patients with post-HCT IRIS related to mycobacterial infection, in vitro data demonstrate the emergence of pathogen-specific immune responses and a concomitant rise in plasma inflammatory markers.
Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis
Bajaj, Jasmohan S. , O’Leary, Jacqueline G. , García–Tsao, Guadalupe , Kamath, Patrick S. , Biggins, Scott W. , Vargas, Hugo E. , Maliakkal, Benedict, Fallon, Michael B. , Thuluvath, Paul J. , Subramanian, Ram, Reddy, K. Rajender , Vargas, Hugo E , Tandon, Puneeta , Wong, Florence , Lai, Jennifer C. , Thacker, Leroy R.

Mayo Clinic

American Journal of Gastroenterology | June 10, 2019 | Volume: 114 | Issue: 7 | Pages: 1091-1100

10.14309/ajg.0000000000000280 | PMID 31180922 Get It

OBJECTIVES: Nosocomial infections (NIs) can be a major cause of morbidity and mortality in cirrhosis. This study aims to define the determinants of NI development and its impact on 30-day outcomes among hospitalized patients with cirrhosis. METHODS: North American Consortium for the Study of End-Stage Liver Disease enrolled patients with cirrhosis who were admitted nonelectively. Admission variables and 30-day outcomes were compared between patients with and without NI. These were also compared based on whether there was an isolated admission infection, NI, or both. Models were created for NI development using admission variables and for 30-day mortality. RESULTS: The study included 2,864 patients; of which, 15% (n = 436) developed NI. When comparing NI vs no NI, 1,866 patients were found to be infection free, whereas 562 had admission infections only, 228 had only NI, and 208 had both infections. At admission, patients with NI were more likely to be infected and have advanced cirrhosis. NIs were associated with higher rates of acute-on-chronic liver failure, death, and transplant regardless of admission infections. Patients with NI had higher respiratory infection, urinary tract infection, Clostridium difficile infection, fungal infections, and infection with vancomycin-resistant enterococci compared with patients without NI. Risk factors for NIs were admission infections, model for end-stage liver disease (MELD) > 20, systemic inflammatory response syndrome criteria, proton pump inhibitor, rifaximin, and lactulose use, but the regression model (sensitivity, 0.67; specificity, 0.63) was not robust. Age, alcohol etiology, admission MELD score, lactulose use, acute-on-chronic liver failure, acute kidney injury, intensive care unit, and NI increased the risk of death, whereas rifaximin decreased the risk of death. DISCUSSION: NIs are prevalent in hospitalized patients with cirrhosis and are associated with poor outcomes. Although higher MELD scores and systemic inflammatory response syndrome are associated with NI, all hospitalized patients with cirrhosis require vigilance and preventive strategies.
The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
Hari, Priya, Millar, Fraser R. , Tarrats, Núria , Birch, Jodie , Quintanilla, Andrea , Rink, Curtis, Fernández-Duran, Irene , Muir, Morwenna , Finch, Andrew J. , Brunton, Valerie G. , Passos, João F. , Morton, Jennifer P. , Boulter, Luke , Acosta, Juan Carlos , Passos, João F

Mayo Clinic

Science Advances | June 5, 2019 | Volume: 5 | Issue: 6 | Pages: No page available

10.1126/sciadv.aaw0254 | PMID 31183403 Get It

Innate immune sensing is essential for the proinflammatory program in cellular senescence.
Congenital myopathies in the adult neuromuscular clinic
Nicolau, Stefan , Liewluck, Teerin , Tracy, Jennifer A., Laughlin, Ruple S. , Milone, Margherita , Liewluck, T , Nicolau, Stefan

Mayo Clinic

Neurology Genetics | June 5, 2019 | Volume: 5 | Issue: 4 | Pages: No page available

10.1212/nxg.0000000000000341 | PMID 31321302 Get It

Timing of Postoperative Radiotherapy in Surgically Treated HPV‐Positive Oropharyngeal Squamous Cell Carcinoma
Townsend, Melanie, DeWees, T.A. , Gross, Jennifer H. , Daly, Mackenzie, Jackson, Ryan S. , DeWees, Todd, DeWees, Todd A , Gay, Hiram A. , Thorstad, Wade

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 4, 2019 | Volume: 161 | Issue: 2 | Pages: 297-306

10.1177/0194599819847144 | PMID 31159646 Get It

ObjectiveOptimal timing of postoperative radiotherapy (PORT) remains understudied in human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma. Objectives are to determine if delays between surgery and radiotherapy, breaks during radiotherapy, disease, or patient factors are associated with recurrence or survival decrements in HPV‐related disease.DesignRetrospective review.SettingAcademic medical center.SubjectsA total of 240 cases of HPV‐positive oropharyngeal squamous cell carcinoma from 2000 to 2016.MethodsPatient and tumor characteristics (American Joint Committee on Cancer, eighth edition), delays to radiation initiation, and breaks during radiation were recorded. Overall survival (OS) and recurrence‐free survival (RFS) were analyzed.ResultsRFS and OS were not significantly affected by delays to PORT >6 weeks or by treatment intervals >100 days (surgery to PORT completion). Breaks during PORT significantly imparted an OS detriment (hazard ratio [HR], 2.4; 95% CI, 1.2‐4.8). Advanced‐stage disease was significantly associated with reduced RFS and OS. Subgroup analysis of stage I versus stage II/III disease found that >6 weeks to PORT initiation and treatment intervals >100 days did not significantly decrease RFS or OS in either stage group. Advanced‐stage disease was significantly associated with worsened OS (HR, 6.6; 95% CI, 2.3‐19.1) and RFS (HR, 5.3; 95% CI, 1.5‐18.4). Breaks during PORT significantly reduced RFS (HR, 3.6; 95% CI, 1.2‐10.8) and OS (HR, 3.2; 95% CI, 1.2‐9.0) in the stage II/III subset.ConclusionDelays to radiotherapy initiation and prolonged treatment time did not affect recurrence or survival in HPV‐related oropharyngeal disease. Locoregionally advanced disease was consistently associated with worse outcomes. Breaks during PORT may affect recurrence and survival, although larger studies are needed to confirm this finding.